Liposomes Drug Delivery Market

Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.

In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.

Liposomes Drug Delivery Market contains market size and forecasts of Liposomes Drug Delivery in global, including the following market information:

Global Liposomes Drug Delivery Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Liposomes Drug Delivery Market Sales, 2017-2022, 2023-2028, (K Vials)

Global top five Liposomes Drug Delivery companies in 2021 (%)

The global Liposomes Drug Delivery market was valued at 3431.8 million in 2021 and is projected to reach US$ 6506.7 million by 2028, at a CAGR of 9.6% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Liposomal Doxorubicin Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Liposomes Drug Delivery include Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma, Sigma-Tau Group, Fudan-Zhangjiang, Teva Pharmaceutical and CSPC, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Liposomes Drug Delivery manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Liposomes Drug Delivery Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Vials)

Global Liposomes Drug Delivery Market Segment Percentages, by Type, 2021 (%)

Liposomal Doxorubicin

Liposomal Amphoteracin B

Liposomal Paclitaxel

Others

Global Liposomes Drug Delivery Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Vials)

Global Liposomes Drug Delivery Market Segment Percentages, by Application, 2021 (%)

Fungal Infection Therapy

Cancer & Tumor Therapy

Others

Global Liposomes Drug Delivery Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Vials)

Global Liposomes Drug Delivery Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Liposomes Drug Delivery revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Liposomes Drug Delivery revenues share in global market, 2021 (%)

Key companies Liposomes Drug Delivery sales in global market, 2017-2022 (Estimated), (K Vials)

Key companies Liposomes Drug Delivery sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Johnson & Johnson

Gilead Sciences

Pacira

Sun Pharmaceutical

Luye Pharma

Sigma-Tau Group

Fudan-Zhangjiang

Teva Pharmaceutical

CSPC

Novartis

Kingond Pharm

Spectrum Pharmaceuticals

Shanghai New Asia